<p>BioLife Solutions（納斯達克代碼：BLFS - 獲取免費報告）於週四發佈了其財報。該醫療設備供應商報告本季度每股收益為 0.04 美元，超出市場共識預期的（0.03 美元）0.07 美元，Zacks 報道。BioLife Solutions 的淨利潤率為負的 38.98%，股本回報率為負的 6.61%。BioLife Solutions 更新了其 2025 財年的每股收益指引。</p>
<p>獲取 <strong>BioLife Solutions</strong> 的提醒：</p>
<h2>BioLife Solutions 股票上漲 3.9%</h2>
<ul>
<li>現在值得投資的最佳生物科技股票</li>
</ul>
<p>週五午盤交易中，BLFS 的股價上漲 0.88 美元，達到 23.24 美元。該公司的交易量為 1,161,730 股，而其平均交易量為 385,880 股。BioLife Solutions 的 1 年最低價為 17.70 美元，1 年最高價為 29.55 美元。該公司的市值為 11 億美元，市盈率為-21.92，貝塔值為 2.01。該公司的債務與股本比率為 0.03，速動比率為 1.78，流動比率為 2.78。該公司的 50 日簡單移動平均線為 23.84 美元，200 日簡單移動平均線為 25.27 美元。</p>
<h2>分析師設定新目標價</h2>
<p>幾家研究公司最近對 BLFS 發佈了報告。HC Wainwright 將 BioLife Solutions 的目標價從 27.00 美元上調至 30.00 美元，並在 3 月 6 日的研究報告中給予該股票 “買入” 評級。StockNews.com 在 4 月 24 日的研究報告中將 BioLife Solutions 的評級從 “持有” 下調至 “賣出”。一位股票研究分析師給予該股票 “賣出” 評級，六位分析師給予該股票 “買入” 評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價為 31.17 美元。</p>
<ul>
<li>3 只小型醫療股今日市場波動</li>
</ul>
<p><strong>查看我們對 BioLife Solutions 的最新股票分析</strong></p>
<h2>內部人士買賣情況</h2>
<p>在其他新聞中，執行副總裁 Aby J. Mathew 於 4 月 1 日（星期二）出售了 10,589 股公司股票。該股票以平均價格 22.66 美元出售，總交易額為 239,946.74 美元。交易完成後，該執行副總裁現在直接持有 309,576 股公司股票，價值約為 7,014,992.16 美元。這代表其持股減少了 3.31%。該交易在向 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，首席財務官 Troy Wichterman 於 4 月 1 日（星期二）出售了 25,687 股股票。該股票以平均價格 22.66 美元出售，總價值為 582,067.42 美元。交易完成後，首席財務官現在持有 189,242 股公司股票，價值約為 4,288,223.72 美元。該交易使其持股減少了 11.95%。該銷售的披露信息可以在這裏找到。在過去的九十天裏，內部人士已出售 72,127 股公司股票，價值 1,676,533 美元。公司內部人士持有公司股票的 2.20%。</p>
<h2>BioLife Solutions 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>BioLife Solutions, Inc.在美國、歐洲、中東、非洲及國際市場開發、製造和銷售細胞和基因治療（CGT）行業的生物生產工具和服務。該公司的產品用於生物基療法的基礎和應用研究以及商業生產。</p>
<h2>另見</h2>
<ul>
<li>五隻我們更看好的股票，勝過 BioLife Solutions</li>
<li>如何使用 MarketBeat 股票篩選器</li>
<li>GlobalFoundries 股票觸底：反彈即將來臨？</li>
<li>何時出售股票以獲利或虧損</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>分析師最青睞的比特幣礦工 CleanSpark：值得關注嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 BioLife Solutions 嗎？</h2>
<p>在你考慮 BioLife Solutions 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 BioLife Solutions 並不在名單上。</p>
<p>雖然 BioLife Solutions 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BLFS

<p>BioLife Solutions（納斯達克代碼：BLFS）報告的季度每股收益為 0.04 美元，超出預期的-0.03 美元，超出幅度為 0.07 美元。儘管淨利潤率為-38.98%，股本回報率為-6.61%，但股價仍上漲 3.9%，達到 23.24 美元。分析師設定的共識目標價為 31.17 美元，HC Wainwright 將其目標價從 27.00 美元上調至 30.00 美元。內部人士減持股票的情況被注意到，管理層減少了持股。BioLife Solutions 專注於細胞和基因治療行業的生物生產工具</p>

<p>BioLife Solutions (NASDAQ:BLFS - Get Free Report) posted its earnings results on Thursday. The medical equipment provider reported $0.04 earnings per share for the quarter, beating the consensus estimate of ($0.03) by $0.07, Zacks reports. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. BioLife Solutions updated its FY 2025 guidance to EPS.</p>
<div class="lb-trans"><p>BioLife Solutions（納斯達克代碼：BLFS - 獲取免費報告）於週四發佈了其財報。該醫療設備供應商報告本季度每股收益為 0.04 美元，超出市場共識預期的（0.03 美元）0.07 美元，Zacks 報道。BioLife Solutions 的淨利潤率為負的 38.98%，股本回報率為負的 6.61%。BioLife Solutions 更新了其 2025 財年的每股收益指引。</p>
</div><p>Get <strong>BioLife Solutions</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>BioLife Solutions</strong> 的提醒：</p>
</div><h2>BioLife Solutions Stock Up 3.9 %</h2>
<div class="lb-trans"><h2>BioLife Solutions 股票上漲 3.9%</h2>
</div><ul>
<li>Best Biotech Stocks to Invest in Now</li>
</ul>
<div class="lb-trans"><ul>
<li>現在值得投資的最佳生物科技股票</li>
</ul>
</div><p>Shares of BLFS traded up $0.88 during midday trading on Friday, hitting $23.24. The company had a trading volume of 1,161,730 shares, compared to its average volume of 385,880. BioLife Solutions has a 1 year low of $17.70 and a 1 year high of $29.55. The firm has a market capitalization of $1.10 billion, a P/E ratio of -21.92 and a beta of 2.01. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. The company's 50-day simple moving average is $23.84 and its 200-day simple moving average is $25.27.</p>
<div class="lb-trans"><p>週五午盤交易中，BLFS 的股價上漲 0.88 美元，達到 23.24 美元。該公司的交易量為 1,161,730 股，而其平均交易量為 385,880 股。BioLife Solutions 的 1 年最低價為 17.70 美元，1 年最高價為 29.55 美元。該公司的市值為 11 億美元，市盈率為-21.92，貝塔值為 2.01。該公司的債務與股本比率為 0.03，速動比率為 1.78，流動比率為 2.78。該公司的 50 日簡單移動平均線為 23.84 美元，200 日簡單移動平均線為 25.27 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析師設定新目標價</h2>
</div><p>Several research firms recently issued reports on BLFS. HC Wainwright increased their target price on BioLife Solutions from $27.00 to $30.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, March 6th. StockNews.com lowered shares of BioLife Solutions from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Thursday, April 24th. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $31.17.</p>
<div class="lb-trans"><p>幾家研究公司最近對 BLFS 發佈了報告。HC Wainwright 將 BioLife Solutions 的目標價從 27.00 美元上調至 30.00 美元，並在 3 月 6 日的研究報告中給予該股票 “買入” 評級。StockNews.com 在 4 月 24 日的研究報告中將 BioLife Solutions 的評級從 “持有” 下調至 “賣出”。一位股票研究分析師給予該股票 “賣出” 評級，六位分析師給予該股票 “買入” 評級。根據 MarketBeat 的數據，該股票的平均評級為 “適度買入”，共識目標價為 31.17 美元。</p>
</div><ul>
<li>3 Small-Cap Medical Stocks Moving Markets Today</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只小型醫療股今日市場波動</li>
</ul>
</div><p><strong>View Our Latest Stock Analysis on BioLife Solutions</strong></p>
<div class="lb-trans"><p><strong>查看我們對 BioLife Solutions 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>內部人士買賣情況</h2>
</div><p>In other news, EVP Aby J. Mathew sold 10,589 shares of the company's stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total transaction of $239,946.74. Following the completion of the transaction, the executive vice president now directly owns 309,576 shares of the company's stock, valued at approximately $7,014,992.16. This represents a 3.31 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Troy Wichterman sold 25,687 shares of the stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $22.66, for a total value of $582,067.42. Following the completion of the transaction, the chief financial officer now owns 189,242 shares in the company, valued at approximately $4,288,223.72. The trade was a 11.95 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 72,127 shares of company stock worth $1,676,533. Company insiders own 2.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他新聞中，執行副總裁 Aby J. Mathew 於 4 月 1 日（星期二）出售了 10,589 股公司股票。該股票以平均價格 22.66 美元出售，總交易額為 239,946.74 美元。交易完成後，該執行副總裁現在直接持有 309,576 股公司股票，價值約為 7,014,992.16 美元。這代表其持股減少了 3.31%。該交易在向 SEC 的法律文件中披露，可以通過此鏈接訪問。此外，首席財務官 Troy Wichterman 於 4 月 1 日（星期二）出售了 25,687 股股票。該股票以平均價格 22.66 美元出售，總價值為 582,067.42 美元。交易完成後，首席財務官現在持有 189,242 股公司股票，價值約為 4,288,223.72 美元。該交易使其持股減少了 11.95%。該銷售的披露信息可以在這裏找到。在過去的九十天裏，內部人士已出售 72,127 股公司股票，價值 1,676,533 美元。公司內部人士持有公司股票的 2.20%。</p>
</div><h2>BioLife Solutions Company Profile</h2>
<div class="lb-trans"><h2>BioLife Solutions 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.</p>
<div class="lb-trans"><p>BioLife Solutions, Inc.在美國、歐洲、中東、非洲及國際市場開發、製造和銷售細胞和基因治療（CGT）行業的生物生產工具和服務。該公司的產品用於生物基療法的基礎和應用研究以及商業生產。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than BioLife Solutions</li>
<li>How to Use the MarketBeat Stock Screener</li>
<li>GlobalFoundries Stock Hits Bottom: Is a Rebound Coming?</li>
<li>When to Sell a Stock for Profit or Loss</li>
<li>Here's The Reason Goldman Sachs Is Bullish On MercadoLibre Stock</li>
<li>How to invest in marijuana stocks in 7 steps</li>
<li>Analyst-Favorite Bitcoin Miner CleanSpark: Worth the Hype?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 BioLife Solutions</li>
<li>如何使用 MarketBeat 股票篩選器</li>
<li>GlobalFoundries 股票觸底：反彈即將來臨？</li>
<li>何時出售股票以獲利或虧損</li>
<li>高盛看好 MercadoLibre 股票的原因</li>
<li>如何在 7 個步驟中投資大麻股票</li>
<li>分析師最青睞的比特幣礦工 CleanSpark：值得關注嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxGUw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsChart.ashx?Prefix=NASDAQ&amp;Symbol=BLFS"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in BioLife Solutions Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 BioLife Solutions 嗎？</h2>
</div><p>Before you consider BioLife Solutions, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 BioLife Solutions 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 BioLife Solutions 並不在名單上。</p>
</div><p>While BioLife Solutions currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 BioLife Solutions 目前在分析師中獲得 “買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

BioLife Solutions (NASDAQ:BLFS) 公佈了財報結果，每股收益比預期高出 0.07 美元